Skip to main content
. 2024 Nov 14;16(12):3089–3112. doi: 10.1038/s44321-024-00169-0

Figure 2. Validation of the diagnostic efficacy of SLMS.

Figure 2

(AC) The ROC curves of SLMS, CEA, CA19-9, and CA72-4 to differentiate gastric cancer patients (all stages) from healthy donors in the training, testing and external validation cohorts. (D, E) The diagnostic performance of SLMS in targeted lipidomics data. AUC area under curve, CA19-9 carbohydrate antigen 199, CA72-4 carbohydrate antigen 724, CEA carcinoembryonic antigen, CI confidence interval, HD healthy donor, ROC receiver operating characteristic, SLMS serum lipid metabolic signature.